Insider Trading in Focus: Pluristem Therapeutics Incorporated (PSTI)

Pluristem Therapeutics Inc. (NASDAQ:PSTI) insider has recently participated in insider trading activity. CFO, COO & President, YANAY YAKY bought 5,000 shares for $ 4,139via one transaction Feb 12. Following the transaction, the insider now owns 46,499 shares in total, priced at $49288.94 as of Tuesday. Another notable insider trading was done by the same insider on Nov 16. YANAY YAKY acquired 10,000 shares at an average price of $1.52 for a total of $ 41,499. CEO & Chairman, Aberman Zami bought 31,000 shares for $ 24,716 via one transaction Feb 11. Following the transaction, the insider now owns 91,400 shares in total, priced at $96884 as of Tuesday. Another notable insider trading was done by the same insider on Nov 16. Aberman Zami acquired 9,900 shares at an average price of $1.49 for a total of $14,751.

The stock has experienced a total of 12 insider trades in the past three months. These trades include 0 sell activities and 12 buy trades. Furthermore, over the past 12 months, the stock was traded 22 times by insiders. In 1 of these trades, the insider was a seller while an employee of the company was the buyer in just 21 instances.

On February 10, 2016, Pluristem Therapeutics Inc. (PSTI) a leading developer of placenta-based cell therapy products, reported financial highlights for its second quarter ended December 31, 2015, and provided clinical and corporate updates.

“We achieved significant clinical milestones during our second fiscal quarter. PLX-R18, our second product, was cleared by the FDA for clinical studies. The PLX-R18 product is designed to be an entirely new and innovative treatment approach for a wide variety of hematopoietic disorders, and might save the lives of severely ill patients with no alternative treatment options. Receipt of an Orphan Drug Designation from the FDA for PLX-PAD cells in the treatment of severe preeclampsia encourages us to move forward with the development plan of this indication,” stated Pluristem Chairman and CEO Zami Aberman. “In both Europe and Japan, we are working with regulators to expedite commercialization of PLX-PAD in the treatment of critical limb ischemia, and we are very pleased that Japanese regulators approved the protocol for our pivotal Phase 2 trial in that indication.”

Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. Its patented placenta expanded (PLX) cells function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals generated by the patient. The company’s PLX cells are grown using proprietary 3D micro-environment technology that produces an off-the-shelf allogeneic cell therapy products.